Delivery Order SPE2DR25D1104-SPE2DR26FK490
- Not listed
- AmerisourceBergen Drug Corp received a delivery order award from the Defense Logistics Agency (DLA) on August 26, 2025, for the supply of Rabavert rabies vaccine with diluents. This is a firm fixed price contract with a ceiling value of $1,676.64 and an ultimate completion date of August 27, 2025. The contract is a child order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on July 16, 2025, for the supply of Rabavert rabies vaccine with diluents. This firm fixed price delivery order, valued at $62,874.00, is scheduled for completion by July 17, 2025, and represents a non-set-aside competitive award. The contract will be performed at the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $5,239.50 delivery order to AmerisourceBergen Drug Corp for Rabavert rabies vaccine with diluents, with an ultimate completion date of September 18, 2025. This competitively awarded, firm fixed price contract carries no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader federal procurement relationships,...
- The Defense Logistics Agency (DLA) awarded a $2,164.34 delivery order to AmerisourceBergen Drug Corp for Rabavert rabies vaccine with diluents. This non-competitive delivery order, issued on November 17, 2025, with a completion date of November 18, 2025, represents a small-value pharmaceutical procurement under a firm fixed-price arrangement. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Rabavert rabies vaccine with diluents, valued at $18,968.07. This firm fixed-price delivery order, which is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), represents a non-competitive set-aside procurement. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $2,029.00 delivery order to AmerisourceBergen Drug Corp for Rabavert rabies vaccine with diluents under a firm fixed price contract. This award, issued on November 24, 2025, with a completion date of November 25, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract was competitively awarded without set-aside designation and will be performed at the...
- The Defense Logistics Agency awarded a delivery order valued at $10,145 to AmerisourceBergen Drug Corp for Rabavert rabies vaccine with diluents, with an ultimate completion date of November 26, 2025. This non-set-aside, competitively awarded delivery order employs firm fixed pricing and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger contract vehicle with DLA. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Rabavert rabies vaccine with diluents under a firm fixed-price contract valued at $6,287.40. The delivery order, issued on September 4, 2025, with an ultimate completion date of September 25, 2025, represents a non-set-aside competitive award. The vaccine will be supplied to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office operations. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Rabavert rabies vaccine with diluents. This firm fixed price delivery order, valued at $2,840.90, represents a non-competitive award under an existing contract vehicle and is scheduled for completion by August 26, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a $30,134.91 delivery order to AmerisourceBergen Drug Corp for Rabavert rabies vaccine with diluents. This is a firm fixed-price, non-set-aside contract with a completion date of April 9, 2025, issued on April 8, 2025. AmerisourceBergen's place of performance is located in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order represents a tactical procurement fulfilling immediate medical supply needs within...
- SPE2DR25D1104Indefinite Delivery Contract
- SPE2DR25D1104-SPE2DR26FK490Delivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a delivery order award from the Defense Logistics Agency for Rabavert rabies vaccine with diluents valued at $3,246.40. This competitively awarded, firm fixed-price delivery order, with no set-aside designation, was issued on November 25, 2025, with an ultimate completion date of November 26, 2025. The contract represents a small-value transaction for critical medical supplies supporting federal healthcare procurement needs. This delivery order falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical commodities to support military healthcare programs worldwide. The vaccine delivery supports the Defense Health Agency and other government healthcare systems requiring specialized pharmaceutical products across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 11/24/25 |